- Joined
- 3 Nov 2010
- Messages
- 26,684
- Solutions
- 7
- Reaction score
- 35,915
Hyderabad: International Drug Discovery and Clinical Research (IDDCR) and Temple University's School of Pharmacy (TUSP) on Thursday announced that they have joined hands to offer global certificate programmes in India.
Under the tie-up, IDDCR will bring US-based Temple University's globally recognised Quality Assurance/Regulatory Affairs (QA/RA) graduate program to students. Starting in late August, they will be one-year post-graduate diploma programmes that cover key concepts in the pharmaceutical industry.
Vamsi Maddipatla, CEO of IDDCR, told a news conference that IDDCR intends to educate 80-100 select students in clinical trial management and global pharmaco vigilance each year. The certificate programmes are expected to help meet the demand for high-quality resources in big pharma, biotechnology, and clinical research organisations in India.
"We are excited to partner with Temple University in bringing their globally acknowledged certificate programme in India as our pharmaceutical industry is currently grappling with a talent crunch," he said.
The certificates consist of five concentrated courses and offer students the option of pursuing the Master's degree of Science at TUSP in the US.
Set up in Hyderabad five years ago, IDDCR is into data management for global pharma majors and also trains students in drug discovery and clinical research. It currently has one training facility here and plans to set up a second facility in Bangalore in six months.
Vamsi said with its operations in India and the US, IDDCR currently has an annual turnover of $4 million and expects to reach $25 million in three years with plans to expand its operations to Europe. IANS
Under the tie-up, IDDCR will bring US-based Temple University's globally recognised Quality Assurance/Regulatory Affairs (QA/RA) graduate program to students. Starting in late August, they will be one-year post-graduate diploma programmes that cover key concepts in the pharmaceutical industry.
Vamsi Maddipatla, CEO of IDDCR, told a news conference that IDDCR intends to educate 80-100 select students in clinical trial management and global pharmaco vigilance each year. The certificate programmes are expected to help meet the demand for high-quality resources in big pharma, biotechnology, and clinical research organisations in India.
"We are excited to partner with Temple University in bringing their globally acknowledged certificate programme in India as our pharmaceutical industry is currently grappling with a talent crunch," he said.
The certificates consist of five concentrated courses and offer students the option of pursuing the Master's degree of Science at TUSP in the US.
Set up in Hyderabad five years ago, IDDCR is into data management for global pharma majors and also trains students in drug discovery and clinical research. It currently has one training facility here and plans to set up a second facility in Bangalore in six months.
Vamsi said with its operations in India and the US, IDDCR currently has an annual turnover of $4 million and expects to reach $25 million in three years with plans to expand its operations to Europe. IANS
